Volume 7, Number 4Review ArticlesThree-Dimensional (3D) Vision: Does It Improve Laparoscopic Skills? An Assessment of 3D Head-Mounted Visualization SystemTechnology UpdateGerald L AndrioleSam B BhayaniLaparoscopic surgery3-Dimensional visualizationEndoSite 3Di
Volume 11, Number 4Review ArticlesThe Impact of Prostate Cancer and Hormonal Therapy on BoneManagement ReviewGerald L AndrioleLarge-scale studies agree that the observed decline in prostate cancer mortality that began in the early 1990s, shortly after prostate-specific antigen testing was introduced in the United States, is most likely explained by more widespread treatment of prostate cancer, including hormonal therapy. Practitioners should be aware of the risk of the development of osteoporosis and of skeletal side effects related to hormonal therapy to optimize the care of men with prostate cancer.[Rev Urol. 2009;11(4):185-189 doi: 10.3909/riu0469]© 2009 MedReviews®, LLCAndrogen deprivation therapyHormone deprivation therapyBonedestructionOsteoporosisOsteopenia
Volume 22, Number 4Review ArticlesLow Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples From Clinical PracticeManagement UpdateGerald L AndrioleFranklin GaylisKelly K BreePaul DatoChristopher J KaneA Karim KaderBroad-based prostate-specific antigen (PSA) screening has saved lives but at a substantial human and financial cost. One way of mitigating this harm, while maintaining and possibly improving the benefit, is by focusing screening efforts on men at higher risk. With age, race, and family history as the only risk factors, many men lack any reliable data to inform their prostate cancer (PCa) screening decisions. Complexities including history of previous negative biopsies, interpretation of negative and/or equivocal mpMRI findings, and patient comorbidities further compound the already complicated decisions surrounding PCa screening and early detection. The authors present cases that provide real-world examples of how a single nucleotide polymorphism–based test can provide patients and providers with personalized PCa risk assessments and allow for development of improved risk-stratified screening regimens. [Rev Urol. 2020;22(4):152–158] © 2021 MedReviews®, LLCProstate cancer screeningRisk stratificationSomatic DNA testGermline DNA testsSingle nucleotide polymorphism DNA test